Abhishek Kumar: New Horizons in Hemophilia B Treatment and Prevention
Abhishek Kumar, Lead Analyst at DelveInsight Business Research LLP, shared a post on LinkedIn:
“Hemophilia B: Genetics, Clotting Challenges, and Modern Treatment Advances
Hemophilia B is a rare inherited bleeding disorder caused by factor IX deficiency due to F9 gene mutations.
It follows an X linked recessive pattern, affecting mostly males while females are carriers.
Reduced factor IX disrupts the intrinsic coagulation pathway, leading to unstable clots and prolonged bleeding after injury.
Severity depends on factor levels.
Management focuses on replacing factor IX through recombinant or plasma derived concentrates, used on demand or prophylactically.
Newer options like extended half life therapies and gene therapy aim to improve long term control and quality of life.
Early diagnosis and care are essential for preventing complications.
Recent Developments in Hemophilia B Clinical Research
In March 2025, Sanofi announced that the U.S. Food and Drug Administration (FDA) approved Qfitlia, the first antithrombin-lowering (AT) therapy for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients (aged 12 or older) with Hemophilia A or B, with or without factor VIII or IX inhibitors.
The approval was based on data from the ATLAS phase 3 studies, which demonstrated clinically meaningful bleed protection as measured by annualized bleeding rates (ABR) across Hemophilia A and B patients, regardless of inhibitor status.
Key Hemophilia B Companies shaping the competitive landscape include: BIOCAD, Gyre Therapeutics, Be Biopharma, Regeneron Pharmaceuticals, Inc., Intellia Therapeutics, Inc., Suzhou Alphamab Co., Ltd., Equilibra Bioscience, UBI Pharma Inc., Staidson (Beijing) Biopharmaceuticals Co., Ltd, and others.
Explore in-depth insights and future market projections today.”
Stay updated with Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy